Watch ORKA. Know when insiders buy.
One email the day a filing lands. Free.
ORKA
Oruka Therapeutics, Inc.
79.92
+0.83 +1.05%
USD · Oct 21, 07:40 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
46
WATCH · insiders 25, shorts 66
Insiders, 90 days
−$14.5M
net selling · 0 buys, 40 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.3BP/E —DIV YIELD —FCF YIELD -1.91%REV TTM —NET INCOME −$132.9MNET CASH —52W 26.19 – 113.08NEXT EARNINGS Nov 11 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$50.1M | −$41.2M | — | — | −$33.1M | $0 | −$33.1M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$36.4M | −$31.8M | — | — | −$23.6M | $73K | −$23.7M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$34.4M | −$29.6M | — | — | −$22.6M | $63K | −$22.7M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$34.1M | −$30.3M | — | — | −$21.6M | $99K | −$21.7M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$28.4M | −$24.6M | — | -0.46 | −$23.1M | $34K | −$23.2M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$25.1M | −$21M | — | -0.40 | −$20.9M | $13K | −$20.9M | Aug 10 |
| Q3 2024 · Sep 30 | — | — | — | −$29.4M | −$28.6M | — | -1.46 | — | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$21.5M | −$22.2M | — | -6.96 | −$2.6M | — | — | Aug 11 |
| Q1 2024 · Mar 31 | $0 | — | — | −$2.5M | −$2M | — | -0.14 | −$1.5M | — | — | Aug 1 |
| Q4 2023 · Dec 31 | $0 | — | — | −$1.6M | −$1.1M | — | -0.08 | −$1.1M | — | — | Aug 1 |
| Q3 2023 · Sep 30 | $0 | — | — | −$1.9M | −$1.4M | — | -0.10 | −$1.7M | — | — | Aug 1 |
| Q2 2023 · Jun 30 | $0 | — | — | −$2M | −$1.5M | — | -0.10 | −$694K | — | — | Aug 1 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$122.1M | −$105.4M | — | — | −$88.2M | $209K | −$88.4M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$7.3M | −$5.3M | — | -0.37 | −$5M | $0 | −$5M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$10.6M | −$9.9M | — | -0.69 | −$10.9M | $2K | −$10.9M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$19.3M | −$19.3M | — | -1.39 | −$18.8M | $43K | −$18.8M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$9.8M | −$9.7M | — | -2.07 | −$7.7M | $19K | −$7.7M | — | — |
| FY2019 · to Dec 31 | $0 | — | −$5.8M | −$5.5M | — | -4.15 | −$4.8M | $4K | −$4.8M | — | — |
Every number comes from Oruka Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.